In the wake of the FDA's decision to hold an Advisory Committee to learn more about #donanemab's unique trial design, our CSO, @a_hfillit, connected with @PharmaVoice on what this means for the #Alzheimers space & recent breakthroughs in #DrugDevelopment: bit.ly/43n2JJj
0
1
2
445
1
Download Image